×
About 3,548 results

ALLMedicine™ Acute Promyelocytic Leukemia Center

Research & Reviews  1,169 results

Recognizing the microgranular variant of acute promyelocytic leukemia when considering ...
https://doi.org/10.1111/trf.17195
Transfusion Gisriel SD, Chen PH et. al.

Nov 26th, 2022 - Recognizing the microgranular variant of acute promyelocytic leukemia when considering leukapheresis.|2022|Gisriel SD,Chen PH,Tormey CA,Siddon AJ,|

An effective and chemotherapy-free strategy of all-trans retinoic acid and arsenic trio...
https://doi.org/10.1038/s41408-022-00753-y
Blood Cancer Journal; Wang HY, Gong S et. al.

Nov 21st, 2022 - The combination of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) has been demonstrated to have comparable effectiveness or better to ATRA and chemotherapy (CHT) in non-high-risk acute promyelocytic leukemia (APL). However, the efficacy...

Synergistic effects of PI3K inhibition and pioglitazone against acute promyelocytic leu...
https://doi.org/10.1002/mgg3.2106
Molecular Genetics & Genomic Medicine; Esmaeili S, Yousefi AM et. al.

Nov 19th, 2022 - Although pioglitazone, a well-known anti-diabetic agent, has recently established itself as a pillar of cancer treatment, its therapeutic value could be attenuated by the aberrant activation of the PI3K/Akt pathway. To evaluate whether the PI3K/Ak...

Arsenic Trioxide Sensitizes Pancreatic Cancer Cells to Gemcitabine through downregulati...
https://doi.org/10.1016/j.trsl.2022.11.007
Translational Research : the Journal of Laboratory and Cl... Tian Z, Tan Y et. al.

Nov 19th, 2022 - Gemcitabine (GEM) is the first-line medication for pancreatic ductal adenocarcinoma (PDAC). However, over some treatment cycles, GEM sensitivity declines and chemotherapeutic resistance develops, resulting in tumor recurrence and metastasis. There...

Multimodal approach to characterize the tetrameric form of human PML-RBCC domain and AT...
https://doi.org/10.1016/j.ijbiomac.2022.11.022
International Journal of Biological Macromolecules; Dubey S, Mishra N et. al.

Nov 11th, 2022 - RING-B box-coiled coil (RBCC) domain of promyelocytic leukemia (PML) comprises a zinc finger motif that is targeted by arsenic trioxide (ATO) to treat acute promyelocytic leukemia (APL) pathogenesis. Preliminary evidence suggests that the PML-RBCC...

see more →

Guidelines  2 results

NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021.
https://doi.org/10.6004/jnccn.2021.0002
Journal of the National Comprehensive Cancer Network : JN... Pollyea DA, Bixby D et. al.

Jan 7th, 2021 - The NCCN Guidelines for Acute Myeloid Leukemia (AML) provide recommendations for the diagnosis and treatment of adults with AML based on clinical trials that have led to significant improvements in treatment, or have yielded new information regard...

Acute myeloid leukemia, version 2.2013.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161234
Journal of the National Comprehensive Cancer Network : JN... O'Donnell MR, Tallman MS et. al.

Sep 14th, 2013 - These NCCN Guidelines Insights summarize several key updates to the NCCN Guidelines for Acute Myeloid Leukemia and discuss the clinical evidence that support the recommendations. The updates described in this article focus on the acute promyelocyt...

see more →

Drugs  14 results see all →

Clinicaltrials.gov  82 results

Phase III Trial in Acute Promyelocytic Leukemia Patients
https://clinicaltrials.gov/ct2/show/NCT00482833

Oct 12th, 2022 - Arm I: Induction therapy: Patients receive oral tretinoin twice daily and arsenic trioxide IV over 2 hours on days 1-60. Patients achieving hematological complete remission go on to receive consolidation therapy. Consolidation therapy: Patients re...

The Acute Promyelocytic Leukaemia Asian Consortium (APL-AC) Project
https://clinicaltrials.gov/ct2/show/NCT04251754

Oct 4th, 2022 - Acute promyelocytic leukemia (APL) is characterized by t(15;17)(q24;21) and the fusion gene PML-RARA.1 In newly-diagnosed patients, optimal supportive care together with the use of all-trans retinoic acid (ATRA) and chemotherapy results in first c...

Oral Arsenic Trioxide for Newly Diagnosed Acute Promyelocytic Leukaemia
https://clinicaltrials.gov/ct2/show/NCT03624270

Oct 4th, 2022 - Acute promyelocytic leukemia (APL) is characterized by t(15;17)(q24;21) and the fusion gene PML-RARA. We have formulated an oral preparation of As2O3 (oral-As2O3), and shown that it is efficacious for APL in R1, inducing CR2 in more than 90% of pa...

Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
https://clinicaltrials.gov/ct2/show/NCT01409161

Sep 30th, 2022 - PRIMARY OBJECTIVES: I. Assess whether a combination of all-trans retinoic acid (ATRA [tretinoin]), and arsenic trioxide (ATO) can produce long-term event-free survival in patients with low-risk untreated acute promyelocytic leukemia (APL). II. Ass...

The Effect of Arsenic Trioxide on Eliminating HIV-1 Reservoir Combined With cART
https://clinicaltrials.gov/ct2/show/NCT03980665

Sep 14th, 2022 - Although combined antiretroviral therapy (cART) could control human immunodeficiency virus type 1 (HIV-1) infection, the persistence of HIV-1 viral reservoir make it extremely difficult to achieving cure of AIDS. The shock and kill strategy has be...

see more →

News  151 results

First Patient Dosed With Menin Inhibitor BMF-219 in COVALENT-101 Trial in CLL
https://www.onclive.com/view/first-patient-dosed-with-menin-inhibitor-bmf-219-in-covalent-101-trial-in-cll

Nov 21st, 2022 - The first patient in the chronic lymphocytic leukemia (CLL) cohort has been dosed in the phase 1 COVALENT-101 trial (NCT05153330), which is evaluating the first-in-class covalent menin inhibitor BMF-219, in patients with relapsed/refractory acute ...

Gilteritinib Induces Encouraging Responses in Newly Diagnosed FLT3-Mutated AML
https://www.onclive.com/view/gilteritinib-induces-encouraging-responses-in-newly-diagnosed-flt3-mutated-aml

Oct 7th, 2022 - Gilteritinib (Xospata), in combination with induction and consolidation chemotherapy, generated responses in patients with newly diagnosed acute myeloid leukemia (AML), including those with FLT3 mutations, according to data from a phase 1 trial (N...

Women in Oncology: How Early Treatments Paved the Way for Future Advances
https://www.onclive.com/view/women-in-oncology-how-early-treatments-paved-the-way-for-future-advances

Aug 18th, 2022 - Catherine E. Lai, MD, MPH, an associate professor and physician leader of the Leukemia Clinical Research Unit at the University of Pennsylvania Perelman Center for Advanced Medicine, moderates a discussion with Selina M. Luger, MD, FRCPC; Gail J. ...

Potential Role of Tamibarotene in AML
https://www.onclive.com/view/potential-role-of-tamibarotene-in-aml

Jun 28th, 2022 - Daniel Pollyea, MD, MS: Tamibarotene is a really interesting drug. About 30% of patients with non–APL [acute promyelocytic leukemia] AML [acute myeloid leukemia] overexpress RARA, which is a type of transcription factor. When we add an agonist aga...

Tamibarotene Highlights Novel Treatment Strategy in RARA+ AML
https://www.onclive.com/view/tamibarotene-highlights-novel-treatment-strategy-in-rara-aml

Jun 27th, 2022 - Retinoic acid receptor α (RARA), a gene overexpressed in approximately 30% of unfit patients with newly diagnosed acute myeloid leukemia (AML), has emerged as a potential therapeutic target. The overexpression of RARA in AML has been correlated wi...

see more →

Patient Education  1 results see all →